Abstract
Soluble amyloid β (Aβ) oligomers might trigger early cognitive deficit in Alzheimers Disease (AD) through the impairment of proper neuronal network function. We have recently shown that the short sequence Aβ25-35 affects the spontaneous activity in hippocampal slices, when was added to the bath, at high nanomolar concentrations. In the present study, we aimed to characterize the effects of the oligomerized full length sequence Aβ1-42 on the spontaneous network activity in the CA1 hippocampal area testing whether such effects are age dependent. By performing extracellular field recordings of spontaneous network activity of hippocampal slices, we found that an oligomerized solution of Aβ1-42 (osAβ) potently inhibit, in a dose-dependent manner, the spontaneous hippocampal network activity with an IC50 of 0.4 ± 3.2 nM and a maximal effect reached around 10 nM. While spontaneous hippocampal network activity is unaffected by age, the sensitivity of spontaneous hippocampal network activity to osAβ (10 nM) appears to be increased in slices from older animals. Moreover, to see a significant reduction in spontaneous network activity in slices from animals in their second week of life 100nM osAβ was needed. The osAβ-induced reduction in hippocampal network activity is accompanied by a presynaptic reduction in both spontaneous and miniature synaptic potentials. Finally, we demonstrated that the effect produced by osAβ on spontaneous network activity was specific, reversible and unrelated with cell death. In conclusion, our data show that osAβ alters hippocampal network activity at concentrations commonly observed in AD patients and that such effect of osAβ increases with age.
Keywords: Alzheimer's disease, amyloid β oligomers, hippocampal spontaneous activity, age
Current Alzheimer Research
Title: Amyloid β Oligomers Decrease Hippocampal Spontaneous Network Activity in an Age-Dependent Manner
Volume: 7 Issue: 5
Author(s): H. Balleza-Tapia, A. Huanosta-Gutierrez, A. Marquez-Ramos, N. Arias and F. Pena
Affiliation:
Keywords: Alzheimer's disease, amyloid β oligomers, hippocampal spontaneous activity, age
Abstract: Soluble amyloid β (Aβ) oligomers might trigger early cognitive deficit in Alzheimers Disease (AD) through the impairment of proper neuronal network function. We have recently shown that the short sequence Aβ25-35 affects the spontaneous activity in hippocampal slices, when was added to the bath, at high nanomolar concentrations. In the present study, we aimed to characterize the effects of the oligomerized full length sequence Aβ1-42 on the spontaneous network activity in the CA1 hippocampal area testing whether such effects are age dependent. By performing extracellular field recordings of spontaneous network activity of hippocampal slices, we found that an oligomerized solution of Aβ1-42 (osAβ) potently inhibit, in a dose-dependent manner, the spontaneous hippocampal network activity with an IC50 of 0.4 ± 3.2 nM and a maximal effect reached around 10 nM. While spontaneous hippocampal network activity is unaffected by age, the sensitivity of spontaneous hippocampal network activity to osAβ (10 nM) appears to be increased in slices from older animals. Moreover, to see a significant reduction in spontaneous network activity in slices from animals in their second week of life 100nM osAβ was needed. The osAβ-induced reduction in hippocampal network activity is accompanied by a presynaptic reduction in both spontaneous and miniature synaptic potentials. Finally, we demonstrated that the effect produced by osAβ on spontaneous network activity was specific, reversible and unrelated with cell death. In conclusion, our data show that osAβ alters hippocampal network activity at concentrations commonly observed in AD patients and that such effect of osAβ increases with age.
Export Options
About this article
Cite this article as:
Balleza-Tapia H., Huanosta-Gutierrez A., Marquez-Ramos A., Arias N. and Pena F., Amyloid β Oligomers Decrease Hippocampal Spontaneous Network Activity in an Age-Dependent Manner, Current Alzheimer Research 2010; 7 (5) . https://dx.doi.org/10.2174/156720510791383859
DOI https://dx.doi.org/10.2174/156720510791383859 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cytochrome P450 in Neurological Disease
Current Drug Metabolism Sleep-Wake Patterns and Cognition of Older Adults with Amnestic Mild Cognitive Impairment (aMCI): A Comparison with Cognitively Healthy Adults and Moderate Alzheimer’s Disease Patients
Current Alzheimer Research Epilepsy, Comorbidities and Treatments
Current Pharmaceutical Design Alzheimer’s Disease, Astrocytes and Kynurenines
Current Alzheimer Research Molecular Mechanism of a Specific NLRP3 Inhibitor to Alleviate Seizure Severity Induced by Pentylenetetrazole
Current Molecular Pharmacology Classical and New Renin-Angiotensin Signalling in Atherosclerosis
Current Signal Transduction Therapy Synthesis and Anticonvulsant Activity of Some Novel 2-Methyl Imidazole Derivatives
Letters in Drug Design & Discovery On Various Metrics Used for Validation of Predictive QSAR Models with Applications in Virtual Screening and Focused Library Design
Combinatorial Chemistry & High Throughput Screening Imaging of Muscarinic Receptors in the Central Nervous System
Current Pharmaceutical Design Investigation of the Roles of New Antiepileptic Drugs and Serum BDNF Levels in Efficacy and Safety Monitoring and Quality of Life: A Clinical Research
Current Clinical Pharmacology Herbal Medicine in the Treatment of Epilepsy
Current Drug Targets ENaC in the Brain - Future Perspectives and Pharmacological Implications
Current Molecular Pharmacology Exogenous Progesterone: A Potential Therapeutic Candidate in CNS Injury and Neurodegeneration
Current Medicinal Chemistry Old Strategies and New Perspectives in Modulating the Endocannabinoid System
Current Bioactive Compounds Interleukin-1β Increases Release of Endothelin-1 and Tumor Necrosis Factor as Well as Reactive Oxygen Species by Peripheral Leukocytes During Experimental Subarachnoid Hemorrhage
Current Neurovascular Research Agonists and Antagonists of Metabotropic Glutamate Receptors: Anticonvulsants and Antiepileptogenic Agents?
Current Neuropharmacology Longitudinal Melatonin Production in Female Laboratory Rats During 1997-2006: Possible Modulatory Effects of Changing Solar Activity
Current Aging Science Topiramate in the New Generation of Drugs: Efficacy in the Treatment of Alcoholic Patients
Current Pharmaceutical Design Mitochondriotropic Cationic Vesicles A Strategy Towards Mitochondrial Gene Therapy
Current Pharmaceutical Biotechnology Some Highlights on Epileptic EEG Processing
Recent Patents on Biomedical Engineering (Discontinued)